CapitolRadar tracks every publicly disclosed MRNA trade by US congress members and corporate insiders: 46 disclosed trades (22 buys, 24 sells) by 3 tracked traders, from 2020-05-22 to 2026-09-24. Updated daily from official filings.
🔥 In the news right now: MRNA picked up 35 news headlines in the last 48 hours. Attention is not evidence. It tells you what people are looking at, not whether they are right.
Want a ping when Congress buys MRNA? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Moderna, Inc. (MRNA) — Healthcare · Biotechnology, market cap about $74.4B.
Cluster watch: 3 distinct tracked traders disclosed buying MRNA in the last 45 days: Ro Khanna, Klinger Shannon Thyme (officer: Chief Legal Officer), Mock James M (officer: Chief Financial Officer).
CapitolRadar analysis
43 trades leaned slightly toward sales
43 tracked MRNA trades were disclosed by three distinct traders from May 22, 2020 through August 19, 2026. The total includes 20 buys and 23 sells, so sales exceeded buys by three transactions. That is a relatively balanced count—about 47% buys and 53% sells—rather than a strongly one-sided record. The activity concerns Moderna, Inc., a Healthcare / Biotechnology company.
18 of 20 buys came from Ro Khanna
Ro Khanna accounted for 18 purchases, or 90% of all tracked MRNA buys, with his latest listed purchase on July 25, 2025. Maria Elvira Salazar recorded one buy, most recently on August 19, 2026, while Josh Gottheimer recorded one, most recently on March 31, 2023. This concentration means the purchase history largely reflects one trader rather than broad participation. With only three distinct traders—and only one purchase each from two of them—the sample is small.
Among these three MRNA buyers, two also bought GOOGL, two bought MRK, two bought ADI, two bought FCX, and two bought PANW. One also bought AMD. The data does not specify whether the same pair accounts for each two-buyer overlap.
21 trades appear in the eight listed quarters
The eight quarterly snapshots contain 21 trades and 10 buys. The busiest listed periods were 2024 Q1, 2023 Q3, and 2023 Q2, each with four trades and two buys. The other listed quarters had one or two trades, underscoring that quarter-level observations are also small. Congressional transaction disclosures may lag trades by up to 45 days, so reported activity is not necessarily contemporaneous. Transaction values are generally disclosed as ranges, making dollar amounts estimates rather than exact figures; no transaction amounts are provided here.
Analysis written from the tracked record on 2026-09-11; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 5 | 3 | 2 |
| 2026 Q1 | 1 | 0 | 1 |
| 2025 Q3 | 2 | 1 | 1 |
| 2024 Q3 | 2 | 1 | 1 |
| 2024 Q1 | 4 | 2 | 2 |
| 2023 Q4 | 2 | 1 | 1 |
| 2023 Q3 | 4 | 2 | 2 |
| 2023 Q2 | 4 | 2 | 2 |
Who is buying MRNA?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 20 | 2026-09-11 | — |
| Maria Elvira Salazar | 1 | 2026-08-19 | — |
| Josh Gottheimer | 1 | 2023-03-31 | — |
Disclosed trades in MRNA
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar | sell | $1,001 - $15,000 | — |
| 2026-09-11 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-09-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-08-19 | Maria Elvira Salazar | buy | $1,001 - $15,000 | — |
| 2026-08-19 | Maria Elvira Salazar | sell | $1,001 - $15,000 | — |
| 2026-01-29 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-08-26 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-07-25 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-09-09 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-09-09 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2024-03-20 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2024-02-13 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-02-01 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-01-10 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-11-03 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-10-02 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-09-15 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2023-08-29 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-08-03 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-07-28 | Ro Khanna | sell | $1,001 - $15,000 | — |
CapitolRadar signal history
NEW PICK 2026-09-07
Rep. Ro Khanna was reported to have bought Moderna stock, joining one company officer who also bought shares recently. The panel passed because no official filing, exact trade date, amount, or entry price was provided, so the claimed timing before positive trial news could not be verified. A primary disclosure confirming the purchase date and showing it occurred before the news, along with the amount and price, could have changed the verdict.
These buyers also bought
Other stocks the tracked buyers of MRNA disclosed buying in the last six months: AMD (2) · RSG (2) · MRK (2) · ADI (2) · GOOGL (2) · MSFT (2).
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respi…
Frequently asked questions
Which politicians bought MRNA most?
Ro Khanna leads with 20 disclosed buys, followed by Maria Elvira Salazar.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.